RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152
Publication date: May 2017 Source:European Journal of Cancer, Volume 77 Author(s): Cecile M. Ronckers, Lieve Tytgat, Marry M. van den Heuvel-Eibrink, Jop Teepen, Leontine C.M. Kremer, Sarah Clement, Hanneke M. van Santen
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου